Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

Lauren G. Aoude(Translational Research Institute), Andrew P. Barbour(Princess Alexandra Hospital)

Scientific Reports

October 19, 2020

10.1038/s41598-020-74956-3

Cited by 44

Related Papers

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

|Nature|2011|474

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients

|Molecular Cancer Research|2021|35